Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

NanoNeuroOmics Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology

Coordinator
The University of Manchester, United Kingdom
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101163249

What the project is doing

In the project's own words, from its summary on CORDIS.

NanoNeuroOmics ambition is to bring together nanotechnology, proteomics and blood biomarker discovery at the emerging intersection of neurodegeneration and neurooncology. NanoNeuroOmics proposes a nanotechnology-based innovative solution for the integrative profiling of the blood and brain tissue proteomes to address two interconnected challenges: i) The unmet clinical need for early diagnostic and disease-monitoring blood biomarkers for two of the most challenging Central Nervous System disorders, namely Alzheimer’s disease (AD) and Glioblastoma (GBM); and ii) The AD-GBM ‘inverse comorbidity’ knowledge gap and intriguing molecular interrelation.

NanoNeuroOmics presents a novel approach, in which nanoparticles are employed as scavenging agents to uncover brain disease-specific protein markers in blood, otherwise buried under the overwhelming signal of highly abundant molecules. NanoNeuroOmics aims to tackle the technological challenge of discovering highly specific blood biomarkers, by longitudinally tracking blood and brain proteomic signals at different stages of disease progression.

To leverage its full potential, the proposed research programme combines longitudinal preclinical studies with human patient clinical validation studies. Such multi-dimensional proteomic approaches are expected to pioneer new blood biomarker discoveries and to provide mechanistic insight into the comorbidity of neurological diseases. NanoNeuroOmics attempts to discover a distinct set of dysregulated proteins for each of AD and GBM independently and to unveil overlapping molecular pathways to explain the AD-GBM inverse comorbidity.

In a broader context, NanoNeuroOmics aspires to bridge the gap between brain pathophysiology and molecular alterations in the blood, across the biological continuum of disease progression. The project takes on a multidisciplinary approach and builds on breakthroughs in nanotechnology and omics sciences, to advance early detection and stratified medicine.

Topics

Who is involved

OrganisationCityCountryRole
The University of ManchesterManchesterUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI